Purchase this article with an account.
Hyoung Jun Koh, Min Kim, Eun Jee Chung, Yong Min Kim; Longitudinal Correlation Of SD-OCT parameters And Angiographic Features With Visual Acuity In Patients With Exudative Age-related Macular Degeneration During Intravitreal Ranibizumab Treatment. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4885.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the association of spectral domain optical coherence tomography (SD-OCT) derived measurement of retinal morphology and fluorescein angiogram (FA) retinal parameters with visual acuity (VA) in neovascular age-related macular degeneration (AMD) patients treated with three consecutive monthly intravitreal ranibizumab injections.
We retrospectively reviewed 51 eyes of 51 patients with subfoveal CNV secondary to AMD and longitudinally analyzed for correlation of SD-OCT and FA with the change in VA using a linear mixed model during three monthly intravitreal ranibizumab therapies. At baseline and at postoperative 1 month, 2 months, and 3 months, best corrected visual acuity (BCVA), intraocular pressure (IOP), SD-OCT derived measurements of retinal morphology were recorded for all patients. FA was recorded before the treatment and at 3 months postoperatively.
Longitudinal correlational analysis demonstrated that decreased central retinal volume (CRV) and central retinal thickness (CRT) were found to be significantly associated with increased VA (p<0.05). Fluorescein leakage area and greatest linear dimension of CNV had a significant association with VA change (p<0.05). Furthermore, decreased CRV and CRT provided good correlation with reduced CNV leakage in FA (p<0.0001).
CRV and CRT measured by SD-OCT, and GLD and CNV leakage area measured by FA demonstrated treatment related correlation with change in VA. These factors accounted for substantial portion of improvement in VA while patients undergo initial therapeutic phase and may presumably be useful in making decisions for subsequent retreatment on an as-needed basis after initial three monthly ranibizumab therapies.
This PDF is available to Subscribers Only